Form 4: Intra-Cellular Therapies CEO Sharon Mates Acquires 104,909 Restricted Stock Units
SEC Form 4 Filing
Sharon Mates, Chairman, President, and CEO of Intra-Cellular Therapies, Inc., was granted 104,909 restricted stock units on March 1, 2024, according to a Form 4 filing.
Summary
- On March 1, 2024, Sharon Mates, the Chairman, President, and CEO of Intra-Cellular Therapies, Inc., received 104,909 restricted stock units.
- These restricted stock units vest in three equal annual installments, starting on the first anniversary of the grant date.
- Each restricted stock unit represents the right to receive one share of Intra-Cellular Therapies common stock.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The grant of restricted stock units is a common practice and aligns management's interests with shareholders. There are no explicit negative implications.
Positives
- The grant of restricted stock units to the CEO aligns her interests with those of the shareholders.
Future Outlook
The restricted stock units vest over three years, incentivizing long-term performance.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders.
Stakeholder Impact
- The grant of restricted stock units aligns the CEO's interests with those of the shareholders, potentially leading to increased shareholder value.
Key Dates
| Date | Description |
|---|---|
| 03/01/2024 | Date of transaction: Sharon Mates granted 104,909 restricted stock units. |
| 03/05/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.